Wegovy Cost in 2026: List Price, Savings, and Alternatives

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This explainer lives in the PlexusDx Education Hub. Browse every Peptides & GLP-1 guide for the wider library.

"Wegovy cost" is among the most-searched questions in the GLP-1 space, and the answer is layered rather than a single number. This overview covers the published list price, the manufacturer and pharmacy discount routes, how insurance shapes the bill, and the compounded-pharmacy alternatives that exist in this market, all as of April 2026 and reported as published rather than promised. The Education Hub holds the deeper guides.

The published list price

Wegovy's list price is approximately $1,349 per month at U.S. list as of April 2026, per Novo Nordisk's published pricing. What a person actually pays depends on insurance coverage, the FDA-approved indication written on the prescription, manufacturer savings programs, and the pharmacy where the prescription is filled. List price is rarely what most insured patients pay, but it anchors every other figure in the conversation.

How insurance shapes the bill

Coverage hinges on whether the prescription is for an FDA-approved indication and on the specific plan's formulary. Many commercial plans cover semaglutide for type 2 diabetes, while coverage for chronic weight management is more variable and often subject to prior authorization or BMI-based criteria. The most reliable move is to check directly with your plan, since two people with similar prescriptions can face different coverage outcomes.

Savings programs and discounts

Novo Nordisk publishes a manufacturer savings card that can substantially reduce monthly out-of-pocket cost for eligible commercially-insured patients. Independent pharmacy discount platforms such as GoodRx and SingleCare publish coupon prices that vary by pharmacy. Eligibility and savings amounts shift over time, so verifying on the manufacturer website or with your pharmacy at the time of fill is the dependable approach.

The FDA shortage context

Between 2022 and 2024, the FDA listed semaglutide on its drug shortage list, which opened a regulatory pathway for licensed 503A compounding pharmacies to compound semaglutide formulations. The FDA resolved the semaglutide shortage in 2024, narrowing but not eliminating that pathway. Legitimate compounded protocols, when prescribed by a licensed clinician through a state-licensed compounding pharmacy, remain a real option, though pricing and access vary.

PlexusDx Weight Management Protocols

PlexusDx offers clinician-supervised compounded GLP-1 protocols inside its Weight Management Protocols, including Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral, alongside Microdose GLP-1 and GLP-Squared options. Each product page lists current pricing as of April 2026. PlexusDx does not sell or recommend other GLP-1 category peptides such as dulaglutide, liraglutide, retatrutide, or cagrilintide.

The genetic context PlexusDx adds

Upstream of any protocol decision, the PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, and MC4R that shape baseline appetite regulation and energy balance. This is pathway education from 503A-aligned testing. It does not predict your response to any specific medication and is not pharmacogenomic; it is the context PlexusDx applies to every cost and protocol conversation.

Putting the pieces together

Read as a whole, the cost picture is a layered one: a high list price at the top, insurance and indication deciding how much of it you see, savings programs and coupons trimming the remainder, and a separately priced compounded pathway sitting alongside the brand. No single figure captures all of that, which is why quoted prices differ so much. Understanding the layers, rather than chasing one number, is what makes the landscape navigable.

For anyone weighing options, the useful move is to identify which layer applies to their own situation first, then verify the current terms at the time of fill. Prices and program rules shift, so a figure that was accurate months ago may not hold today.

Frequently Asked Questions

How much does Wegovy cost without insurance?

Wegovy's list price is approximately $1,349 per month at U.S. list as of April 2026, per Novo Nordisk's published pricing. Without insurance and without a savings card, that list figure is what cash-pay patients face at most U.S. pharmacies. Compounded alternatives, manufacturer savings programs, and pharmacy discount cards can substantially reduce out-of-pocket cost for those who qualify.

Is there a savings card for Wegovy?

Yes. Novo Nordisk publishes a manufacturer savings card that can substantially reduce monthly out-of-pocket cost for eligible commercially-insured patients. Independent coupons from GoodRx and SingleCare also publish discounted prices that vary by pharmacy and change frequently. Verify eligibility and current terms at the time of fill, since amounts shift over time.

Why is Wegovy priced so high?

Wegovy is a patent-protected branded medication, and its list price reflects factors such as research-cost recovery, market positioning, and expected payer mix. Prices stayed high in part because demand outpaced manufacturing in 2023 and 2024. Savings programs and compounded alternatives are the main levers patients use to bring the effective cost down.

Are compounded versions cheaper?

Often yes. Compounded semaglutide from licensed 503A pharmacies has historically been priced below Wegovy's list price. The trade-offs include regulatory complexity, variation in prescriber oversight, and the FDA's evolving stance following the 2024 shortage resolution. Whether it is appropriate is a decision to discuss with a qualified clinician.

This explainer lives in the PlexusDx Education Hub. Browse every Peptides & GLP-1 guide for the wider library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.